

Edgar Filing: NEUROCRINE BIOSCIENCES INC - Form 8-K

NEUROCRINE BIOSCIENCES INC
Form 8-K
November 16, 2001

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 8-K

Current Report
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 16, 2001

Neurocrine Biosciences, Inc.
(Exact name of registrant as specified in its charter)

| | | |
|---|-------------------------------------|---|
| Delaware (State or Other Jurisdiction of Incorporation) | 0-28150 (Commission File Number) | 33-0525145 (I.R.S. Employer Identification No.) |
|---|-------------------------------------|---|

| | |
|---|---------------------|
| 10555 Science Center Drive, San Diego, California (Address of Principal Executive Offices) | 92121 (Zip Code) |
|---|---------------------|

Registrant's telephone number, including area code: (858) 658-7600

This Current Report on Form 8-K is filed by Neurocrine Biosciences, Inc., a Delaware corporation (the "Company"), in connection with the matters described herein.

Item 5. Other Events.

On November 16, 2001, the Company announced that it has initiated the first pivotal Phase III clinical trial of NBI-34060 in approximately 500 patients with chronic (primary) insomnia. A copy of the Company's press release announcing the initiation of the clinical trial, dated November 16, 2001, is attached hereto as Exhibit 99.1 and incorporated herein by reference.

Item 7. Exhibits.

| (c) | Exhibits. Exhibit Number | Description of Exhibit |
|-----|--------------------------------|------------------------|
| | ----- | ----- |

Edgar Filing: NEUROCRINE BIOSCIENCES INC - Form 8-K

99.1

Press Release, dated November 16, 2001.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 16, 2001

NEUROCRINE BIOSCIENCES, Inc.

By: /s/ PAUL W. HAWRAN

Paul W. Hawran
Senior Vice President and
Chief Financial Officer